Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LY2 | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 10264.011 | uM | 2.47060 | 23.53780 | -0.6543 | -0.9921 | 0.4850 | 0.5557 | 0.9929 | 1.3983 | |
LY2 | HR+ | Luminal | Oxamflatin | HDAC | HDAC | 12319.147 | uM | 0.92816 | 1.95770 | -0.8875 | -0.9090 | 1.3881 | 0.6226 | 0.9379 | 1.1783 | |
LY2 | HR+ | Luminal | Oxamflatin | HDAC | HDAC | 10816.147 | uM | 1.46430 | 2.2370 | -0.9835 | -0.9829 | 2.5654 | 0.5014 | 0.9979 | 0.7283 | |
LY2 | HR+ | Luminal | PD 98059 | MEK | MAPK | 10816.152 | uM | inf | inf | 0.6055 | 0.6055 | 0.0000 | 0.0662 | 0.4985 | 1.0111 | |
LY2 | HR+ | Luminal | PD173074 | FGFR1/3 | RTK | 10380.093 | uM | 8.16720 | 9.24270 | -0.4195 | -0.4220 | 4.9463 | 0.0993 | 0.9928 | 1.4880 | |
LY2 | HR+ | Luminal | PD184352 | MEK | MAPK | 10816.155 | uM | inf | inf | 0.5413 | 0.5413 | 0.0000 | 0.0964 | 0.4722 | 0.8353 | |
LY2 | HR+ | Luminal | PD184352 | MEK | MAPK | 10816.155 | uM | inf | inf | 0.5413 | 0.5413 | 0.0000 | 0.0964 | 0.4722 | 0.8353 | |
LY2 | HR+ | Luminal | PD184352 | MEK | MAPK | 12319.155 | uM | inf | inf | 0.7640 | 0.7640 | 0.0000 | 0.0144 | 0.5546 | 0.9333 | |
LY2 | HR+ | Luminal | PD184352 | MEK | MAPK | 12319.155 | uM | inf | inf | 0.7640 | 0.7640 | 0.0000 | 0.0144 | 0.5546 | 0.9333 | |
LY2 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 10380.095 | uM | 0.46671 | 0.30280 | 0.1161 | 0.2841 | 1.9411 | 0.5166 | 0.9207 | 1.4726 | |
LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 10380.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0461 | -60.9713 | 1.4916 | |
LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 7477.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7891 | |
LY2 | HR+ | Luminal | Purvalanol A | CDK1 | CDK | 7477.067 | uM | 204.01150 | 195.37340 | 0.7169 | 0.0973 | 5.0000 | -0.0291 | 0.7971 | 0.6787 | |
LY2 | HR+ | Luminal | Ribavirin | 15391.211 | uM | inf | inf | 0.9725 | 0.9725 | 0.0000 | 0.0076 | -0.0134 | 1.2835 | |||
LY2 | HR+ | Luminal | SB-3CT | MMP2/9 | MMP | 10816.144 | uM | inf | inf | 0.9453 | 0.9453 | 0.0000 | -0.0111 | -0.0185 | 0.9146 | |
LY2 | HR+ | Luminal | SB-3CT | MMP2/9 | MMP | 12319.168 | uM | 6.1160 | 9.60070 | -0.9871 | -0.9793 | 2.4054 | 0.4732 | 0.9758 | 0.9560 | |
LY2 | HR+ | Luminal | Selumetinib | MEK | MAPK | 10816.155 | uM | inf | inf | 0.9135 | 0.9135 | 0.0000 | 0.1047 | 0.4006 | 0.8353 | |
LY2 | HR+ | Luminal | Selumetinib | MEK | MAPK | 12319.155 | uM | inf | inf | 0.6784 | 0.6784 | 0.0000 | 0.1879 | 0.5014 | 0.9333 | |
LY2 | HR+ | Luminal | Sigma A6730 | AKT | AKT | 12319.165 | uM | 1.09610 | 3.0440 | -0.9869 | -1.0000 | 1.0756 | 0.6110 | 0.8753 | 0.9117 | |
LY2 | HR+ | Luminal | Sigma A6730 | AKT | AKT | 10816.153 | uM | 1.79770 | 3.82850 | -0.9957 | -1.0000 | 1.4532 | 0.4976 | 0.9581 | 0.7704 | |
LY2 | HR+ | Luminal | Sirolimus | MTOR | MTOR | 7865.068 | uM | inf | inf | -0.1814 | -0.1814 | 0.0000 | 0.5691 | 0.4192 | 1.5516 | |
LY2 | HR+ | Luminal | Sirolimus | MTOR | MTOR | 7477.069 | uM | 0.11419 | 0.13814 | -0.1474 | -0.0370 | 0.3746 | 0.4594 | 0.7973 | 1.6157 | |
LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 7477.084 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0334 | -0.0852 | 0.9476 | |
LY2 | HR+ | Luminal | Sunitinib | PDGFR/VEGFR/KIT/FLT3 | RTK | 7477.067 | uM | 6.0510 | 7.53770 | -0.9999 | -0.9998 | 5.0000 | 0.4399 | 0.9978 | 0.6787 | |
LY2 | HR+ | Luminal | Taxol | TUBB | TUBB | 10264.002 | uM | 0.01167 | 0.01092 | -0.1629 | 0.0626 | 1.9986 | 0.5515 | 0.9562 | 1.2356 |